Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.

Xu YY, Wang X, She YQ, Liu J, Zhang Q

Endocrine journal22 Jun 2024Cited by 3 (Europe PMC)

PMID38910131DOI10.1507/endocrj.ej24-0168PepBankPUB-38910131

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetes and NAFLD, liraglutide significantly reduced BMI (mean difference -1.06) in a meta-analysis.
In plain wordsIn people with type 2 diabetes and fatty liver, liraglutide lowered BMI in pooled trials.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Comparator
Placebo or other drugs (mainly insulin)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD
−1.06
BMI
Source sentences
Summary
body mass index (mean difference [MD] = -1.06, 95%CI: -1.41, -0.70, p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
The meta-analysis results revealed that liraglutide significantly reduced
Summary · context
This study aimed to systematically evaluate the efficacy of liraglutide in treating type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver disease (NAFLD) by comparing liraglutide with placebo or other drugs (mainly insulin).
Report a problemFND-3891013101
02HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetes and NAFLD, liraglutide significantly reduced triglycerides (mean difference -0.35) in a meta-analysis.
In plain wordsIn people with type 2 diabetes and fatty liver, liraglutide lowered triglycerides in pooled trials.
Peptide
Liraglutide
Outcome
DecreaseTriglycerides
Study
n: not reported in source
Comparator
Placebo or other drugs (mainly insulin)
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD
−0.35
triglycerides
Source sentences
Summary
triglycerides (MD = -0.35, 95%CI: -0.61, -0.09, p = 0.0009)
2 context sentences(design, population, supporting numbers)
Summary · context
The meta-analysis results revealed that liraglutide significantly reduced
Summary · context
This study aimed to systematically evaluate the efficacy of liraglutide in treating type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver disease (NAFLD) by comparing liraglutide with placebo or other drugs (mainly insulin).
Report a problemFND-3891013102
03HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetes and NAFLD, liraglutide significantly reduced visceral adipose tissue (mean difference -21.06) in a meta-analysis.
In plain wordsIn people with type 2 diabetes and fatty liver, liraglutide reduced visceral fat in pooled trials.
Peptide
Liraglutide
Outcome
DecreaseVisceral adipose tissue
Study
n: not reported in source
Comparator
Placebo or other drugs (mainly insulin)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD
−21.06
visceral adipose tissue
Source sentences
Summary
visceral adipose tissue (MD = -21.06, 95%CI: -34.58, -7.55, p = 0.002)
2 context sentences(design, population, supporting numbers)
Summary · context
The meta-analysis results revealed that liraglutide significantly reduced
Summary · context
This study aimed to systematically evaluate the efficacy of liraglutide in treating type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver disease (NAFLD) by comparing liraglutide with placebo or other drugs (mainly insulin).
Report a problemFND-3891013103
04HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetes and NAFLD, liraglutide significantly reduced subcutaneous adipose tissue (mean difference -20.53) in a meta-analysis.
In plain wordsIn people with type 2 diabetes and fatty liver, liraglutide reduced subcutaneous fat in pooled trials.
Peptide
Liraglutide
Outcome
DecreaseSubcutaneous adipose tissue
Study
n: not reported in source
Comparator
Placebo or other drugs (mainly insulin)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD
−20.53
subcutaneous adipose tissue
Source sentences
Summary
subcutaneous adipose tissue (MD = -20.53, 95%CI: -29.15, -11.90, p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
The meta-analysis results revealed that liraglutide significantly reduced
Summary · context
This study aimed to systematically evaluate the efficacy of liraglutide in treating type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver disease (NAFLD) by comparing liraglutide with placebo or other drugs (mainly insulin).
Report a problemFND-3891013104
05HumanSystematic reviewSafety outcome
In a meta-analysis in type 2 diabetes with NAFLD, 2 of 11 studies reported adverse reactions to liraglutide, which were primarily gastrointestinal.
In plain wordsIn pooled trials in type 2 diabetes with fatty liver, 2 of 11 studies reported side effects of liraglutide, mostly in the gut.
Peptide
Liraglutide
Outcome
Not applicableAdverse reactions
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Of the 11 studies, 2 reported the occurrence of adverse reactions, which were primarily gastrointestinal.
1 context sentence(design, population, supporting numbers)
Summary · context
This study aimed to systematically evaluate the efficacy of liraglutide in treating type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver disease (NAFLD) by comparing liraglutide with placebo or other drugs (mainly insulin).
Report a problemFND-3891013105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.